REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Regenxbio (RGNX) Tops Q4 EPS by 45c, Revenues Beat
February 27, 2019 4:24 PM ESTRegenxbio (NASDAQ: RGNX) reported Q4 EPS of $0.11, $0.45 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $40.78 million versus the consensus estimate of $17.33 million.
Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMDCompleted dosing of six additional subjects in the fourth cohort for a total of 12 subjects; 30 subjects dosed across four cohorts in the trialOn-track to initiate Phase IIb trial for wet AMD in late 2019Continues to advance development of RGX-314 for other chronic retinal diseases; new IND submission for... More